12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Exelon rivastigmine regulatory update

Novartis said in its 4Q12 earnings that EMA's CHMP issued a positive opinion recommending expansion of the label of Exelon Patch rivastigmine transdermal patch to include the 13.3 mg/24 hour dose...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >